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ABSTRACT
Bisphosphonates are potent inhibitors of bone resorption, and are used in the treatment of osteoporosis and other diseases 
that cause bone mass loss, such as Paget’s disease, bone metastases, and multiple myeloma, to prevent pathological 
fractures. Since 2003, avascular osteonecrosis of the jaw has been associated with the use of bisphosphonates, mainly 
intravenous. According to the literature, the occurrence of osteonecrosis of the jaw has ranged from 0.8% to 12% of 
the patients on bisphosphonates, most of them on prolonged use. Physicians and odontologists should be aware of that 
potential complication in dental treatment. 
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INTRODUCTION
Bisphosphonates (BFT) are potent inhibitors of bone resorp-
tion, and are used in the treatment of osteoporosis and other 
diseases that cause bone mass loss, such as Paget’s disease, 
bone metastases, and multiple myeloma, to prevent patho-
logical fractures.1 Bisphosphonates increase bone mass and 
mineralization, with an increase in bone mineral density and 
resistance, and a reduction in the risk of bone fracture.
Bisphosphonates show selectivity for areas of bone resorp-
tion and inhibit the action of osteoclasts. In molecular terms, 
one of the major actions of BFT is the inhibition of the enzyme 
farnesyl diphosphate synthase, causing several cytoskeletal 
alterations, reducing the bone resorption capacity of the os-
teoclasts and inducing apoptosis of those cells.1-3 In general, 
BFT are systemically well tolerated. Their adverse effects are 
rare and consist in low and transient fever, fatigue, arthralgia, 
nausea, esophagitis, renal failure, hypocalcemia, and bone 
pain.4 The use of BFT, however, has been associated with cases 
of avascular osteonecrosis of the jaw (Figure 1). Other skeletal 
bones have not been involved. The general symptoms include 
diffi culty in eating and speaking, swelling, pain, bleeding, 
paresthesia of the lower lip, and tooth mobility and loss. The 
radiographic fi ndings are not specifi c, thus, such lesions might 
require biopsy to rule out metastases.5 
This study aimed at reviewing the literature regarding the 
risk of BFT-related avascular osteonecrosis of the jaws, in 
addition to providing guidance for prevention and treatment 
according to the stage of the disease.
REVIEW OF THE LITERATURE
Pamidronate and zoledronate belong to the drug class of bone 
resorption inhibitors, which have been used for years for the 
treatment of osteoporosis. The clinical effi cacy of such drugs 
in the treatment of osteopenia/osteoporosis has been well es-
tablished.6 The presence of nitrogen in their formulation makes 
their metabolization diffi cult, leading to their accumulation in 
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bones and prolonged action.7 Oral BFT have been more often 
indicated for the treatment of osteoporosis and osteopenia. 
They have also been indicated in other less common conditions, 
such as Paget’s disease and osteogenesis imperfecta. Table 1 
shows the characteristics of the BFT indicated for treating 
osteoporosis available in the Brazilian market. 
The association of BFT with osteonecrosis of the jaws 
was fi rst reported in 2003 by Marx.8 The author reported 36 
cases of avascular osteonecrosis, 29 of which in the mandible, 
fi ve in the maxilla, and two in both bones. Of the 36 patients, 
24 were on intravenous (IV) pamidronate, 90 mg monthly; 
six used initially pamidronate at the same dosage, and then 
changed to IV zoledronate, 4 mg monthly; and six received 
only IV zoledronate, 4 mg monthly. The indications for the use 
of those drugs were multiple myeloma-related hypercalcemia 
(18 patients), metastatic breast carcinoma-related hypercal-
cemia (17 patients), and treatment of osteoporosis (one patient). 
After the fi rst report in 2003,8 several studies by oral and 
maxillofacial surgeons have associated the use of BFT with avas-
cular osteonecrosis of the jaws. In December 2004, Novartis, the 
manufacturer of pamidronate and zoledronate, called attention 
to the risk of osteonecrosis.9 A search in the PubMed database 
(U.S. National Library of Medicine and the National Institutes of 
Health) (http://www.ncbi.nlm.nih.gov/sites/entrez) on February 
2nd, 2011, with the descriptors (bisphosphonate) AND (osteone-
crosis of the jaws) identifi ed 928 articles. 
To differentiate from other bone pathologies, the follow-
ing working defi nition of avascular osteonecrosis of the jaw 
has been adopted by the American Association of Oral and 
Maxillofacial Surgeons (AAOMS):10 Patients may be con-
sidered to have BFT-related osteonecrosis of the jaw in the 
presence of all the following three characteristics: 1) previous 
or current treatment with a BFT; 2) exposed, necrotic bone in 
the maxillofacial region that has persisted for more than eight 
weeks; and 3) no history of radiation therapy in the region. 
The cumulative incidence of avascular osteonecrosis of the 
jaw ranges from 0.8% to 12%. It is more often related to the 
intravenous, monthly administration and for a period longer than 
three years. The use of BFT in such conditions is more common 
in the treatment of hypercalcemia secondary to malignant tu-
mors, to bone metastases from breast, prostate, and lung cancer, 
and to osteolytic diseases, such as multiple myeloma.10-12
The oral route is more common in the treatment of osteo-
porosis. Until 2006, according to IMS Health, over 190 mil-
lion oral BFT prescriptions had been dispensed worldwide.10 
Patients under treatment with oral BFT are considered at 
low risk as compared with patients with cancer receiving 
intravenous monthly treatment with BFT, which signifi cantly 
increases the risk of osteonecrosis.11 However, cases of os-
teonecrosis of the jaws have been reported in patients on oral 
BFT.13,14 An Australian control has estimated that the incidence 
for patients treated weekly with alendronate ranges from 0.01% 
to 0.04%.15 Among 13 thousand patients of an American health 
Table 1 
Characteristics of the BFT indicated for treating osteoporosis in Brazil
BFT Primary indication Dose Route Relative potency
Alendronate Osteoporosis 10 mg/day
70 mg/week
Oral 1






Risedronate Osteoporosis 5 mg/day
35 mg/week
Oral 1








Bisphosphonate-related osteonecrosis. Left retromandibular 
region.
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care insurance, receiving oral BFT for a long time, the preva-
lence was 0.06% or 1:1,700 patients.16 
The occurrence of osteonecrosis of the jaw seems to be 
related to the use of intravenous BFT. However, data are inac-
curate, and given the large number of patients being treated for 
osteoporosis, receiving oral BFT for a long period, it is likely 
that many cases may appear in that group of patients, since 
duration of therapy is one of the risk factors.17,18
Comorbidities, such as obesity and the chronic use of cor-
ticoids, can be associated, but that relation has not been clari-
fi ed. The local risk factors include oral surgery, dental implant 
placement, extractions, and periodontal surgery involving bone 
lesions. Local factors also include the presence of bony exos-
toses (lingual and palatal tori) and poorly adapted prostheses. 
Regarding demographic and systemic risk factors, the studies 
are scarce. Gender does not seem to infl uence; however, the 
Caucasian race, advanced age and smoking seem to increase 
the risk, while alcohol consumption does not.18-20
Prior to treatment with intravenous BFT, the patient should 
have a thorough oral examination, all unsalvageable teeth 
should be removed, all invasive dental procedures should be 
completed, the prostheses should be well adapted, and optimal 
periodontal health should be achieved. Therefore, the risk for 
osteonecrosis of the jaw is reduced, but not eliminated.18,19 
Some instructions and protocols for patients at risk for osteo-
radionecrosis seem to be the same for patients under treatment 
with intravenous BFT. When previous surgery is needed, if 
systemic conditions permit, the beginning of the BFT therapy 
should be delayed until the operated area has mucosalized or 
until there is complete osseous healing.10-12 
Table 2 shows staging of osteonecrosis of the jaw and the 
corresponding treatment strategies proposed by the AAOMS 
in 2009.10
The oral use of BFT is not that critical for the risk of avas-
cular osteonecrosis of the jaw. Thus, elective oral surgeries 
are not contraindicated, but the patient should be aware of the 
risk. If systemic conditions permit, interruption of oral BFT 
should be considered for a period of three months before and 
three months after elective surgery to reduce the risk of os-
teonecrosis. That approach is justifi ed based on extrapolated 
data, showing BFT-therapy-related fl uctuations of osteoclast 
function, and on the conclusions of recent studies showing 
better results of the treatment of avascular osteonecrosis of 
the jaw with drug discontinuation.21-23
CONCLUSIONS
There is evidence that the use of bisphosphonates is associated 
with avascular osteonecrosis of the jaw, which is rare and af-
fects the quality of life of patients already physically impaired. 
Patients under the treatment of BFT or who are going to initiate 
that treatment, particularly if intravenous, but also oral, for 
long periods, should be carefully assessed by a physician and 
dental surgeon to avoid osteonecrosis.
Table 2 
Staging and treatment strategies of osteonecrosis of the jaw
Staging Treatment strategy
At risk category
Patient under treatment with either oral or IV 
BFT, with no apparent necrotic bone 
•  No treatment indicated
•  Patient education
Stage 0
No clinical evidence of necrotic bone, but non-
specifi c clinical fi ndings and symptoms
•  Systemic management, including the use of pain medication and antibiotics
Stage 1
Exposed necrotic bone in asymptomatic patients 
with no evidence of infection
•  Oral antibacterial mouth rinse
•  Clinical follow-up on a quarterly basis
•  Patient education and review of indications for continued BFT use 
Stage 2
Exposed necrotic bone with infection as evidenced by pain 
and erythema, with or without purulent drainage
•  Symptomatic treatment with oral antibiotics
•  Oral antibacterial mouth rinse
•  Pain control
•  Superfi cial debridement to relieve soft tissue irritation 
Stage 3
Exposed necrotic bone in patients with pain and erythema 
and one or more of the following: exposed and necrotic bone 
extending beyond the  region of alveolar bone, such as inferior 
border and ramus in the mandible, maxillary sinus or zygoma in 
the maxilla, resulting in pathologic fracture, extra-oral fi stula, oral 
antral/oral nasal communication, or osteolysis extending to the 
inferior border of the mandible or to the maxillary sinus fl oor
•  Oral antibacterial mouth rinse
•  Antibiotic therapy and pain control
•  Debridement/surgical resection for prolonged relieve of pain and infection
Osteonecrose dos maxilares associada ao uso de bisfosfonatos
407Rev Bras Reumatol 2011;51(4):401-7
REFERENCES
REFERÊNCIAS
1. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr 
Mol Med 2002; 2(6):571-7.
2. Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ, Baldock 
PA. Zoledronic acid treatment results in retention of femoral head 
structure after traumatic osteonecrosis in young Wistar rats. J Bone 
Miner Res 2003; 18(11):2016-22.
3. Astrand J, Aspenberg P. Systemic alendronate prevents resorption 
of necrotic bone during revascularization. A bone chamber study in 
rats. BMC Musculoskelet Disord 2002; 7(3):19.
4. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and 
compliance with dosing regimens. Oncologist 2004; 9 (Suppl 4):28-37.
5. Diego R, D’Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti 
G et al. Bisphosphonate-associated osteonecrosis of the jaws: a 
therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod 2007; 103(3):e1-5.
6. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD et 
al. Zoledronic acid is superior to pamidronate in the treatment of 
hypercalcemia of malignancy: a pooled analysis of two randomized, 
controlled clinical trials. J Clin Oncol 2001; 19(2):558-67.
7. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 
1998; 19(1):80-100.
8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced 
avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac 
Surg 2003; 61(9):1115-7.
9. Hohnecker JA. Novartis “Dear Doctor” precautions added to label 
of Aredia and Zometa. September 24, 2004. Citado por Ruggiero 
SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. 
American Association of Oral and Maxillofacial Surgeons. American 
Association of Oral and Maxillofacial Surgeons position paper on 
bisphosphonate-related osteonecrosis of the jaws – 2009 update. J 
Oral Maxillofac Surg 2009; 67(5 Suppl):2-12.
10. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, 
Mehrotra B. American Association of Oral and Maxillofacial 
Surgeons. American Association of Oral and Maxillofacial 
Surgeons position paper on bisphosphonate-related osteonecrosis 
of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67(5 
Suppl):2-12.
11. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg 
D et al. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report 
of a Task Force of the American Society for Bone and Mineral 
Research. J Bone Miner Res 2007; 22(10):1479-91.
12. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S et 
al. Bisphosphonate-related osteonecrosis of the jaw: position paper 
from the Allied Task Force Committee of Japanese Society for Bone 
and Mineral Research, Japan Osteoporosis Society, Japanese Society 
of Periodontology, Japanese Society for Oral and Maxillofacial 
Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. 
J Bone Miner Metab 2010; 28:365-83.
13. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and 
obesity are strong risk factors for osteonecrosis of the jaw: a case-
control study. J Oral Maxillofac Surg 2008; 66(4):625-31.
14. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S. Osteonecrosis 
of the jaws associated with the use of bisphosphonates: a review of 
63 cases. J Oral Maxillofac Surg 2004; 62:527-34.
15. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-
induced exposed bone (osteonecrosis\osteopetrosis) of the jaws: risk 
factors, recognition, prevention and treatment. J Oral Maxillofac 
Surg 2005; 63:1567-75.
16. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of 
bisphosphonate- associated osteonecrosis of the jaws in Australia. 
J Oral Maxillofac Surg 2007; 65:415-23.
17. Ault A. Jaw necrosis affects 1 in 1,700 on oral bisphosphonates. 
Internal Medicine News 2008; 41(Aug 1):23.
18. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos 
I, Bozas G et al. Osteonecrosis of the jaw in cancer after treatment 
with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 
23(34):8580-7.
19. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M 
et al. Frequency and risk factors associated with osteonecrosis of 
the jaw in cancer patients treated with intravenous bisphosphonates. 
J Bone Miner Res 2008; 23(6):826-36.
20. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D 
et al. Incidence, risk factors and management of osteonecrosis of the 
jaw in patients with multiple myeloma: a single-centre experience 
in 303 patients. Br J Haematol 2006; 134(6):620-3.
21. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos 
I, Bozas G et al. Osteonecrosis of the jaw in cancer after treatment 
with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 
23(34):8580-7.
22. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, 
Roussou M et al. Reduction of osteonecrosis of the jaw (ONJ) 
after implementation of preventive measures in patients with 
multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 
20(1):117-20.
23. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, 
Saibene G et al. Decreased occurrence of osteonecrosis of the jaw 
after implementation of dental preventive measures in solid tumor 
patients with bone metastases treated with bisphosphonates. The 
experience of the National Cancer Institute of Milan. Ann Oncol 
2009; 20(1):137-45.
